Effect of Modified Erchentang on Expressions of Chemokine Receptor CXCR1/2 and CXCL8 in Patients with AECOPD
10.13422/j.cnki.syfjx.20192406
- VernacularTitle: 二陈汤加味对急性加重期COPD患者CXCL8及CXCR1/2蛋白表达的影响
- Author:
Li-zhi SHANG
1
;
Shu JI
1
;
Yao-yang LI
1
;
Meng-di MAO
1
;
Guo-qiang WANG
1
;
Long-tao SHI
1
;
Guang-yuan ZHANG
1
;
Li-li XU
1
;
Wen-ying XIE
1
Author Information
1. Henan University of Chinese Medicine, Zhengzhou 450046, China
- Publication Type:Research Article
- Keywords:
chronic obstructive pulmonary disease (COPD);
Erchentang;
peripheral blood mononuclear cells (PBMCs);
inflammation;
chemokine
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(24):1-8
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the clinical efficacy of modified Erchentang on CXC chemokine ligand receptors (CXCR1/2)and their ligands CXCL8,macrophage inflammatory protein -2(MIP-2) in patients of chronic obstructive pulmonary disease(AECOPD)at acute exacerbation stage,and assess the effect and mechanism of modified Erchentang on anti-inflammatory in patients of AECOPD. Method:This study was a multicenter, randomized single blind, controlled trial. The authors selected 200 cases in conformity to the standards of AECOPD. The AECOPD patients were randomly divided into modified Erchentang group and control group. In addition to the western medicine, modified Erchentang was also given to the modified Erchentang group, and Jizhitangjiang was given to the control group for 14 days. Each group was observed for the alleviation of the symptoms. Euzyme-linked immunosorbent assay (ELISA) was used to determine the levels of CXCL8 and MIP-2 in the patients' plasma of all groups before and after treatment. Western blot were used to detect the levels of CXCR1, CXCR2 and CXCL8 protein in peripheral blood mononuclear cells(PBMCs). Immunocytochemistry (ICC) method was used to detect the expressions of CXCL8, CXCR1 and CXCR2 protein in PBMCs. Result:The level of CXCL8 in plasma, and the expressions of CXCR1, CXCR2 and CXCL8 mRNA and protein in the modified Erchentang group were decreased significantly than those in the control group(P<0.05,P<0.01). Conclusion:Modified Erchentang has an anti-inflammatory effect on AECOPD. Its mechanism may be related to the down-regulation of the expressions of CXCL8, CXCR1 and CXCR2, the reduction of synthesis and release of CXCL8 and MIP-2, the inhibition of the chemotaxis and activity of inflammatory cells, and the prevention of inflammation progress.
